Heated Pemetrexed Disodium and Cisplatin during Surgery in Treating Participants with Pleural Malignant Mesothelioma

Inclusion Criteria

• Histologically proven malignant pleural mesothelioma MPM that is considered resectable according to the following criteria: * Confined to one pleural space * No chest wall invasion * No transdiaphragmatic involvement * No invasion of mediastinal structures
• Eastern Cooperative Oncology Group performance status 0-1
• Adequate cardiopulmonary reserve defined as follows as assessed within 4 months of study entry: * Predicted postoperative forced expiratory volume FEV1 > 1L * Normal left ventricular function (ejection fraction EF ≥ 45%) and right ventricular function * No pulmonary hypertension noted on preoperative transthoracic echocardiography
• Completed within 60 days of surgery: Hemoglobin ≥ 9.0 g/dL
• Completed within 60 days of surgery: Absolute neutrophil count (ANC) ≥ 1500/mm^3
• Completed within 60 days of surgery: Platelet count ≥ 100,000/mm
• Completed within 60 days of surgery: Calculated creatinine clearance ≥ 60 mL/min; the creatinine clearance CrCl is determined by the Cockcroft-Gault formula
• Completed within 60 days of surgery: Total bilirubin < 1.5 times the upper limit of institutional normal value
• Completed within 60 days of surgery: Aspartate aminotransferase AST (serum glutamic oxaloacetic transaminase SGOT) and alanine aminotransferase ALT (serum glutamic pyruvic transaminase SGPT) < 3 times the upper limit of the institutional normal
• Completed within 60 days of surgery: International normalized ratio INR ≤ 1.5 in patients not utilizing systemic anticoagulation as part of their medical regimen
• Women of child bearing potential and sexually active males must use an accepted and effective non-hormonal method of contraception
• Patients must be deemed by the investigators to be fully recovered from both acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
• The ability to interrupt non-steroidal anti-inflammatory drugs NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed
• The ability to take folic acid, vitamin B12, and dexamethasone according to protocol

Exclusion Criteria

• Not pregnant or breastfeeding; a negative pregnancy test is required within 14 days of registration for pre- or perimenopausal (i.e., last menstrual period within one year of registration) women
• Patients with a history of another neoplasm, with the exception of non-metastatic, non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or small field radiotherapy, within 5 years of registration will be excluded
• Patients with uncontrolled cardiovascular disease (a history of hospitalization for acute myocardial infarction, arrhythmia, or congestive heart failure within 3 months prior to registration) will be excluded
• Registered patients with an active infection or with a fever of ≥ 38.5 Celsius degrees (C) within 24 hours of the first scheduled day of protocol initiation will be excluded until their infection and/or fever resolves
• Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient’s ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
• Inability to interrupt use of non-steroidal anti-inflammatory drugs (NSAIDS)
• Peripheral neuropathy ≥ grade 2 (Common Terminology Criteria for Adverse Events CTCAE)
• Systemic chemotherapy within 3 weeks of registration
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin and pemetrexed
• Presence of third space fluid which cannot be controlled by drainage